AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?

Key Takeaways AZN will report Q4 results on Feb. 10, with consensus estimates of $15.71B in sales and $2.18 EPS.Key oncology drugs Calquence, Lynparza, Tagrisso and Imfinzi, plus Farxiga, are expected to lead sales.AZN's rare disease portfolio and alliance revenues are seen supporting growth, even as operating costs rise.AstraZeneca (AZN) is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surpr ...